Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

72.81
+0.11000.15%
Post-market: 73.000.1900+0.26%19:30 EDT
Volume:414.07K
Turnover:30.12M
Market Cap:3.20B
PE:-67.27
High:73.08
Open:72.88
Low:71.77
Close:72.70
52wk High:85.25
52wk Low:48.20
Shares:43.88M
Float Shares:32.68M
Volume Ratio:0.67
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:9.21
PE(LYR):-45.79

Loading ...

Tarsus Pharmaceuticals to Report Q2 2026 Results, Host Webcast

Reuters
·
Aug 06

Tarsus Pharmaceuticals is Maintained at Outperform by Mizuho

Dow Jones
·
Aug 01

Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating

MT Newswires Live
·
Jul 31

Tarsus Pharmaceuticals Inc : Mizuho Cuts Target Price to $98 from $100

THOMSON REUTERS
·
Jul 31

Oppenheimer Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Jul 22

Tarsus Pharmaceuticals is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Rxsight Names Aziz Mottiwala CEO, Ron Kurtz to Become Chief Medical Officer

Reuters
·
Jul 16

Tarsus Pharmaceuticals Announces Chief Commercial Officer Transition

TIPRANKS
·
Jul 14

Tarsus Pharmaceuticals chief commercial officer Aziz Mottiwala to depart

TIPRANKS
·
Jul 14

Tarsus CCO Aziz Mottiwala Departs; Neera Clase Named Interim Replacement

Reuters
·
Jul 14

Press Release: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Dow Jones
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Conmed (CNMD) and Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Jul 13

Guggenheim Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Jul 13

Tarsus Pharmaceuticals Price Target Maintained with a $88.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Jul 09

Tarsus Publishes Investor Presentation on Irenix Acquisition, Irx-101 Ocular Antiseptic Program

Reuters
·
Jul 09

Tarsus Pharmaceuticals Buys Irenix Medical in Deal with USD 75 Million Upfront Payment

Reuters
·
Jul 09

Tarsus Pharmaceuticals - Upfront Consideration for Deal Totals $75 Mln: $37.5 Mln Cash, $37.5 Mln Stock

THOMSON REUTERS
·
Jul 09

Tarsus Pharmaceuticals - to Begin Phase 3 Irx-101 Study in H1 2027, Results Expected 2028

THOMSON REUTERS
·
Jul 09

Tarsus Advances Eye Care Leadership Strategy with Acquisition of Irenix Medical and Late-stage Asset Irx-101

THOMSON REUTERS
·
Jul 09